HCPLive Network

Distributing Naloxone to Heroin Users Is Likely Cost-Effective and May Reduce Overdose Deaths

 
FRIDAY, Jan. 4 (HealthDay News) -- Distributing naloxone to heroin users for lay administration for overdose reversal would be cost-effective and likely reduce overdose deaths, according to a study published in the Jan. 1 issue of the Annals of Internal Medicine.

Phillip O. Coffin, M.D., from the San Francisco Department of Public Health, and Sean D. Sullivan, Ph.D., from the University of Washington in Seattle, used published literature calibrated to epidemiological data to analyze scenarios involving a hypothetical 21-year-old novice U.S. heroin user and more experienced users to estimate the cost-effectiveness of distributing naloxone. The overdose deaths prevented and incremental cost-effectiveness ratio (ICER) were assessed using deterministic and probabilistic analyses.

In the best-case analysis, the researchers found that 6 percent of overdose deaths would be prevented with naloxone distribution, with distribution of 227 naloxone kits necessary to prevent one death. Distribution of naloxone correlated with a $53 increase in costs and a 0.119 increase in quality-adjusted life-years, for an ICER of $438. In a worse-case scenario, the estimated ICER was $14,000, where overdose was rarely witnessed and naloxone was seldom used, minimally effective, and expensive. Application of national drug-related expenditures to heroin users would result in an ICER of $2,429. In all deterministic and probabilistic sensitivity and scenario analyses, naloxone distribution was considered to be cost-effective, and if it resulted in fewer overdoses or emergency medical service activations, it was considered cost-saving.

"Naloxone distribution to heroin users is likely to reduce overdose deaths and is cost-effective, even under markedly conservative assumptions," the authors write.
 

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

 
Copyright © 2013 HealthDay. All rights reserved.
 

Further Reading
Scientists from Sanofi Pasteur’s Swiftwater, PA facility have published results of a study indicating that a high-dose, trivalent, inactivated influenza vaccine (IIV3-HD or high dose Fluzone®) improves antibody responses to influenza among adults 65 years of age or older.
Prescription medications for mental health diagnoses (e.g. antidepressants, antipsychotics, and mood stabilizers) consume approximately 25% of commercial health insurers’ pharmacy budgets and almost 35% of public payers’ pharmacy spending. In 2011, an estimated 26.8 million US adults—more than 11%—took prescription medications for mental illness.
A letter published online in the Journal of the American Medical Association presents the first microbiologic pathogens trend analysis in hospitalized patients in the United States.
As people spend more time sitting and working in front of computer screens, studies have shown the risk of developing carpal tunnel syndrome (CTS) has grown. A team of researchers recently worked to take a deeper look at specific factors and their roles in the development in the condition.
Because a key antiviral defense mechanism is present in asthmatics, another defect in their immune system must explain their difficulty combating respiratory viruses, according to researchers from Washington University in St. Louis.
Reports indicate the patient presented with Ebola-like symptoms at a local emergency room and told staff he had recently traveled to Africa. If so, why wasn’t CDC protocol followed, and why was the man sent home?
Concerned about a mysterious outbreak of pediatric paralysis, the US Centers for Disease Control and Prevention (CDC) has asked physicians to report any similar cases. In Denver, CO, 10 children have been admitted to Children’s Hospital Colorado with limb weakness and paralysis since Aug. 1, according to the hospital.
More Reading